The Virology Division at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Md. has a requirement to evaluate the immunogenicity of a novel vaccine platform administered in multiple formulations (28 or 56 days apart) by intramuscular injection to Cynomolgus macaques.
The vendor must be capable of pre-screening all animals and confirm they are negative for the following pathogens: Filoviruses, Alphaviruses, tuberculosis, HMV phenotype of Klebsiella pneumoniae, shigella, salmonella, and Yersinia. The vendor must be able to collect whole blood in serum separator (SST), EDTA K2, Na citrate, and CPT Heparin collection tubes at various time points both pre- and post-vaccination of the animals.
After blood collection, the vendor must be able to process each sample and aliquot accordingly for serum (SST), whole blood (EDTA K2), plasma (Na Citrate), and PBMCs (CPT Heparin) and ship the samples to USAMRIID for additional analysis. If during USAMRIID analysis, it is determined that the animals produced an adequate immune response to the vaccine, the vendor will ship the animals to USAMRIID for additional evaluation; if the animals do not produce an adequate response to the vaccine, then the vendor will dispose of the animals according to their own institute policies and procedures.
Further details are available under Solicitation Number: Solicitation Number: W81XWH-14-T-0112. The response deadline is April 14, 2014.
